JPMorgan Reinstates Stoke Therapeutics (STOK) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall St treads water as chips rise, megacaps fall ahead of Fed, Big Tech earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise about 2% as Yemen fighting stokes supply fears
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts STOK Hot Sheet
Price: $26.16 +0.11%
Rating Summary:
14 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 16 | New: 17
Rating Summary:
14 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 16 | New: 17
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on Stoke Therapeutics (NASDAQ: STOK) with a Neutral rating and a price target of $6.00.
For an analyst ratings summary and ratings history on Stoke Therapeutics click here. For more ratings news on Stoke Therapeutics click here.
Shares of Stoke Therapeutics closed at $4.22 yesterday.
You May Also Be Interested In
- JPMorgan Starts FANUC Corp (6954:JP) (FANUY) at Neutral
- JPMorgan Starts SMC Corp (6273:JP) (SMCAY) at Neutral
- Nomura/Instinet Resumes Nippon Building Fund Incorporation (8951:JP) (NBFJF) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
